-
公开(公告)号：US20230203194A1
公开(公告)日：2023-06-29
申请号：US18067407
申请日：2022-12-16
Applicant: Genentech, Inc.
Inventor： Jeong KIM , Jeanne CHEUNG
IPC: C07K16/32 , A61K31/337 , C07K16/28 , A61K45/06 , A61K47/64 , A61K39/395 , A61K31/282 , C07K16/30
CPC classification number: C07K16/32 , A61K31/337 , C07K16/2809 , C07K16/2818 , A61K45/06 , A61K47/643 , A61K39/39558 , A61K31/282 , A61K39/3955 , C07K16/2803 , C07K16/30 , C07K16/2827 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3069 , A61K2039/505
Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
-
2.发明申请公开(公告)号：US20180256711A1
公开(公告)日：2018-09-13
申请号：US15842380
申请日：2017-12-14
Applicant: Genentech, Inc.
Inventor： Ina P. RHEE , Jeong KIM , Mahrukh HUSENI , Eric STEFANICH , Siddharth SUKUMARAN , Chi-Chung LI
IPC: A61K39/395 , C07K16/28 , A61K9/00 , A61K39/00
CPC classification number: A61K39/3955 , A61K9/0019 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2827 , C07K16/2878 , C07K2317/24 , C07K2317/75 , C07K2317/76
Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
-
3.发明申请公开(公告)号：US20180171025A1
公开(公告)日：2018-06-21
申请号：US15662684
申请日：2017-07-28
Applicant: Genentech, Inc.
Inventor： Jeong KIM
IPC: C07K16/30 , C07K16/28 , A61K39/395 , C07K16/46 , A61K39/00
CPC classification number: C07K16/3061 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2803 , C07K16/2827 , C07K16/2887 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/73 , C07K2317/76
Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an anti-CD20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
-
公开(公告)号：US20210147562A1
公开(公告)日：2021-05-20
申请号：US17081784
申请日：2020-10-27
Applicant: Genentech, Inc.
Inventor： Gregory LAZAR , Jeong KIM , Jing ZHU , Yanli YANG , Randall BREZSKI
IPC: C07K16/28 , C07K16/32 , A61K47/68 , A61K38/02 , A61K39/395
Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
-
公开(公告)号：US20180346586A1
公开(公告)日：2018-12-06
申请号：US15977671
申请日：2018-05-11
Applicant: Genentech, Inc.
Inventor： Ina P. RHEE , Jeong KIM , Mahrukh HUSENI , Eric STEFANICH , Sid SUKUMARAN , Chi-Chung LI
IPC: C07K16/28 , C12Q1/6886 , A61K9/00
CPC classification number: C07K16/2878 , A61K9/0019 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/56 , C07K2317/75 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158
Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
-
Patent Agency Ranking
公开(公告)号：US20250154282A1
公开(公告)日：2025-05-15
申请号：US19027348
申请日：2025-01-17
Applicant: Genentech, Inc.
Inventor： Jeong KIM , Jeanne CHEUNG
IPC: C07K16/32 , A61K31/282 , A61K31/337 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/64 , C07K16/28 , C07K16/30
Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
-
7.发明申请METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS 审中-公开使用抗OX40抗体和PD-1轴结合拮抗剂治疗癌症的方法公开(公告)号：US20170000885A1
公开(公告)日：2017-01-05
申请号：US15176106
申请日：2016-06-07
Applicant: Genentech, Inc.
Inventor： Ina P. RHEE , Jeong KIM , Mahrukh HUSENI , Eric STEFANICH , Sid SUKUMARAN , Chi-Chung LI
IPC: A61K39/395 , A61K9/00
CPC classification number: A61K39/3955 , A61K9/0019 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2827 , C07K16/2878 , C07K2317/24 , C07K2317/75 , C07K2317/76
Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
Abstract translation: 本发明提供治疗或延缓个体中癌症进展的方法，包括向个体施用抗人OX40激动剂抗体和抗PDL1抗体。 在一些实施方案中，抗人OX40激动剂抗体以约0.8mg，约3.2mg，约12mg，约40mg，约80mg，约130mg，约160mg，约300mg， 约320mg，约400mg，约600mg和约1200mg，并且抗PDL1抗体以约800mg或约1200mg的剂量施用。
-
8.发明申请METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY 审中-公开使用PD-1轴绑定拮抗剂和抗CD20抗体治疗癌症的方法公开(公告)号：US20150210772A1
公开(公告)日：2015-07-30
申请号：US14574197
申请日：2014-12-17
Applicant: GENENTECH, INC.
Inventor： Jeong KIM
IPC: C07K16/30 , A61K39/395 , C07K16/46 , C07K16/28
CPC classification number: C07K16/3061 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2803 , C07K16/2827 , C07K16/2887 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/73 , C07K2317/76
Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an anti-CD20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Abstract translation: 本发明描述了包含PD-1轴结合拮抗剂和抗CD20抗体的组合治疗及其使用方法，包括治疗需要增强免疫原性的病症的方法，例如增加用于治疗癌症的肿瘤免疫原性。
-
9.发明申请COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS 审中-公开包含OX40结合激素和PD-1轴结合拮抗剂的组合治疗公开(公告)号：US20150190506A1
公开(公告)日：2015-07-09
申请号：US14574365
申请日：2014-12-17
Applicant: GENENTECH, INC.
Inventor： Jeanne CHEUNG , Jeong KIM
IPC: A61K39/395 , A61K45/06 , A61K38/16
CPC classification number: A61K39/39558 , A61K38/16 , A61K45/06 , A61K2039/507 , A61K2039/55 , C07K16/2827 , C07K16/2878 , C07K2317/75 , C07K2317/76
Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
Abstract translation: 本发明提供了治疗癌症的组合物和方法。 该方法包括施用PD-1轴结合拮抗剂和OX40结合激动剂。
-
公开(公告)号：US20240076404A1
公开(公告)日：2024-03-07
申请号：US18477924
申请日：2023-09-29
Applicant: Genentech, Inc.
Inventor： Jeong KIM , Jeanne CHEUNG
IPC: C07K16/32 , A61K31/282 , A61K31/337 , A61K39/395 , A61K45/06 , A61K47/64 , C07K16/28 , C07K16/30
CPC classification number: C07K16/32 , A61K31/282 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/643 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3069 , A61K2039/505
Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.07 seconds)
